Maternal-fetal considerations of CFTR modulator therapy during pregnancy
Journal of Developmental Origins of Health and Disease · 2026 · 17
DOI: 10.1017/s2040174426100877 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Developmental Origins of Health and Disease, online erschienen am 20.11.2026. Verfasst von Zihanjiao Wang und 8 weiteren Autor:innen. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recent advances in cystic fibrosis (CF) treatment, particularly the development of CFTR modulators (CFTRm), have transformed disease management and substantially improved survival, health status, and reproductive outcomes in people with CF. In addition to lung symptoms, CF is characterised by pancreatic insufficiency, meconium ileus, and reduced fertility, leading to a shorter life expectancy. CFTRm, e.g. elexacaftor-tezacaftor-ivacaftor partially restore CFTR function. Together, these treatments have markedly improved survival and quality of life for individuals with CF. As increasing numbers of women with CF conceive while taking CFTRm, understanding maternal-fetal drug exposure has become a clinical priority. Emerging evidence demonstrates that CFTRm cross the placenta and can be detected in cord blood, neonatal plasma, and infant tissues. However, the extent of fetal exposure, tissue accumulation and potential developmental implications remain incompletely understood. Herein, we emphasise the mechanistic and pharmacological evidence underlying fetal exposure to CFTRm . This review synthesises current evidence regarding the transplacental transfer, fetal exposure and developmental implications of CFTRm during pregnancy. We discuss emerging pharmacokinetic data, reported maternal and infant outcomes and key knowledge gaps that remain regarding the safety of in utero CFTRm exposure.
Zitieren
APA
Wang, Z., Prewer, G., Karunagaran, K., Totaro, A., Li, D., Dobric, A., Rolnik, D. L., Menkhorst, E., & Schneider-Futschik, E. K. (2026). Maternal-fetal considerations of CFTR modulator therapy during pregnancy. Journal of Developmental Origins of Health and Disease, 17. https://doi.org/10.1017/s2040174426100877
Vancouver
Wang Z, Prewer G, Karunagaran K, Totaro A, Li D, Dobric A, et al. Maternal-fetal considerations of CFTR modulator therapy during pregnancy. Journal of Developmental Origins of Health and Disease. 2026;17. doi:10.1017/s2040174426100877
BibTeX
@article{Wang2026,
author = {Wang, Zihanjiao and Prewer, Georgina and Karunagaran, Karishma and Totaro, Ava and Li, Danni and Dobric, Aleksandar and Rolnik, Daniel L. and Menkhorst, Ellen and Schneider-Futschik, Elena K.},
title = {Maternal-fetal considerations of CFTR modulator therapy during pregnancy},
journal = {Journal of Developmental Origins of Health and Disease},
year = {2026},
volume = {17},
doi = {10.1017/s2040174426100877}
}
EUVIMED